v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues        
Services $ 50,163 $ 10,046 $ 55,519 $ 70,300
Product 166,147 29,706 310,599 83,663
Total Revenues 216,310 39,752 366,118 153,963
Operating Expenses        
Research and development 5,451,287 3,279,323 10,356,965 6,869,376
General and administrative 2,644,957 3,085,840 5,226,660 5,687,992
Sales and marketing 1,669,102 1,774,064 3,376,559 3,373,047
Total Operating Expenses 9,765,346 8,139,227 18,960,184 15,930,415
Operating Loss (9,549,036) (8,099,475) (18,594,066) (15,776,452)
Other Income (Expenses)        
Grant income 0 393,440 165,795 393,440
Interest income 27,109 11,161 84,757 11,163
Interest expense (58,321) (37,129) (109,643) (78,161)
Gain on change in fair value of warrant liability 28,971 0 28,971 0
Total Other Income (Expenses) (2,241) 367,472 169,880 326,442
Net Loss (9,551,277) (7,732,003) (18,424,186) (15,450,010)
Net Loss Attributable to Non-Controlling Interest 80,298 82,302 173,659 166,279
Net Loss Attributable to VolitionRx Limited Stockholders (9,470,979) (7,649,701) (18,250,527) (15,283,731)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments 37,712 214,097 (18,766) 96,193
Net Comprehensive Loss $ (9,513,565) $ (7,517,906) $ (18,442,952) $ (15,353,817)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited $ (0.14) $ (0.14) $ (0.29) $ (0.28)
Weighted Average Shares Outstanding        
- Basic and Diluted 66,884,368 53,810,500 63,613,224 53,803,076

Source